問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Thoracic Medicine

Division of Infectious Disease

Division of Pediatrics

Division of General Internal Medicine

Division of Rheumatology

更新時間：2024-06-12

傅彬貴Fu, Pin-Kuei
  • Principal Investigator
  • Clinical Trial Experience (year)

  • yetquen@gmail.com

Recruiting Trial

30Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

傅彬貴

List

47Cases

2025-11-01 - 2030-12-31

Phase II

Not yet recruiting
A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study, to Investigate the Efficacy and Safety of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

  • Condition/Disease

    Chronic obstructive pulmonary disease

  • Test Drug

    prefilled syringe

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

2025-01-31 - 2028-01-30

Phase II

Active
A Randomized, Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Investigate the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig (SAR443765) in Adult Participants With High-risk Asthma Who Are Not Currently Eligible for Biologic Treatment

  • Condition/Disease

    Asthma

  • Test Drug

    Lunsekimig/ SAR443765

Participate Sites
7Sites

Recruiting7Sites

2023-09-30 - 2028-08-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2025-06-01 - 2028-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2022-10-19 - 2024-02-09

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting4Sites

2024-10-31 - 2026-12-31

Phase II

Active
A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Dose Range-Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 Given Once Daily for 12 Weeks in Adults with Uncontrolled Asthma at Risk of Exacerbations (LEVANTE)

  • Condition/Disease

    Asthma

  • Test Drug

    dry powder inhaler

Participate Sites
8Sites

Recruiting8Sites

2024-01-22 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Not yet recruiting7Sites

Recruiting7Sites

2024-03-01 - 2027-12-31

Phase III

Active
A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared with Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function

  • Condition/Disease

    Heart Failure

  • Test Drug

    capsule

Participate Sites
21Sites

Not yet recruiting11Sites

Recruiting10Sites

2025-03-01 - 2030-06-30

Phase III

Active
A Phase III, Randomised, Placebo-controlled, Event-driven Study to Evaluate the Effect of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on the Risk of Incident Heart Failure and Cardiovascular Death

  • Condition/Disease

    To reduce the risk of heart failure events and cardiovascular (CV) death in patients at high risk for developing heart failure.

  • Test Drug

    Baxdrostat Dapagliflozin

Participate Sites
18Sites

Recruiting18Sites

2025-03-01 - 2028-12-31

Phase II

Active
A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adult Participants With Uncontrolled Asthma on Medium-to High Dose Inhaled Corticosteroids

  • Condition/Disease

    Asthma

  • Test Drug

    Tozorakimab

Participate Sites
8Sites

Recruiting8Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB